Effect of Chemical Profiling Change of Processed Magnolia officinalis on the Pharmacokinetic Profiling of Honokiol and Magnolol in Rats
Effect of Chemical Profiling Change of Processed Magnolia officinalis on the Pharmacokinetic Profiling of Honokiol and Magnolol in Rats
复制标题
炮制品厚朴化学成分变化对和厚朴酚和厚朴酚在大鼠体内药代动力学特征的影响
DOI：
10.1093/chromsci/bmw052
复制
发表时间：
2016-08-01
影响因子：
1.3
通讯作者：
Zou, Liang
中科院分区：
文献类型：
--
作者：
Hu, Huiling;Wang, Zhanguo;Zou, Liang
厚朴的茎皮在中药中应用前，通常经过预处理。和厚朴酚（HO）和厚朴酚（MA）的生物利用度以及化学特征变化对HO和MA药代动力学的影响一直是一个比MO更大的挑战。与MO相比，PMO中HO和MA的药代动力学特征明显改变，HO和MA的Tmax分别增加31%和50%（P < 0.05），HO的AUC（0-t）和Cmax分别增加36%和24%（P < 0.05）。随后，通过简单快速的LC-Q/TOF-MS结合多变量分析方法研究了MO和PMO的化学谱。主成分分析和系统聚类分析表明，PMO的化学特征与MO有显著差异。通过偏最小二乘判别分析，筛选出8个标记成分，包括6个生物碱（木兰箭毒碱、木兰花碱、罗梅碱和3个未鉴定峰）和2个木脂素（obovatol和MA）。结果表明，PMO中8种标志物组分的变化可能对HO和MA的药代动力学特征产生影响。
The stem of Magnoliae officinalis (MO) cortex is always preliminarily processed before being applied in traditional Chinese medicine. The definite bioavailability of honokiol (HO) and magnolol (MA) in processed MO (PMO) and the effect of chemical profiling change on the pharmacokinetics of HO and MA are always a greater challenge compared with those of MO. Compared with that of MO, the pharmacokinetic profiling of HO and MA in the PMO was significantly changed and the mean T-max of HO and MA was increased by 31 and 50% (P < 0.05), respectively; the mean AUC(0-t) and C-max of HO were increased by 36 and 24% (P < 0.05), respectively. Subsequently, the chemical profiling of MO and PMO was investigated by a simple and rapid LC-Q/TOF-MS coupled with multivariate analysis method. Principal component analysis and hierarchical cluster analysis of the chromatographic data demonstrated that the chemical profiling of PMO was significantly different from that of MO. Eight marker components including six alkaloids (magnocurarine, magnoflorine, roemerine and three unidentified peaks) and two lignans (obovatol and MA) were screened out by partial least-squares discriminant analysis. The results indicated that the changes of eight marker components of PMO may have an effect on the pharmacokinetic profiles of HO and MA.